Skip to main content

Advertisement

SpringerLink
Log in

How to report adherence to treatment as clinically relevant data—making a case of CML and TKI

  • Letter to the editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aronson JK (2007) Compliance, concordance, adherence. Br J Clin Pharmacol 63:383–384

    Article  PubMed  PubMed Central  Google Scholar 

  2. Breccia M, Efficace F, Alimena G (2012) Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leuk Res 36:804–805

    Article  PubMed  Google Scholar 

  3. Moulin SM, Eutrópio FJ, Souza JO et al (2017) The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer 25:951–955

    Article  PubMed  Google Scholar 

  4. Vrijens B, Goetghebeur E, de Klerk E et al (2005) Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 24:2719–2731

    Article  PubMed  Google Scholar 

  5. Okumura LM, Antunes VD, Aguiar KS et al (2015) Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment. Pharm Pract (Granada) 13:559

    Article  Google Scholar 

  6. Guilhot J, Preudhomme C, Mahon FX et al (2015) Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. Cancer 121:490–497

    Article  PubMed  Google Scholar 

  7. Morisky DE, Ang A, Krousel-Wood M et al (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348–354

    Article  Google Scholar 

  8. Gater A, Heron L, Abetz-Webb L et al (2012) Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 36:817–825

    Article  PubMed  Google Scholar 

  9. Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ganesan P, Sagar TG, Dubashi B (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471–474

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author was given a monthly scholarship from the Brazilian Ministry of Education, by the time the letter was conceived (Residência Integrada Multiprofissional em Saúde).

Author information

Authors and Affiliations

  1. Clinical Pharmacy Division, Hospital de Clínicas de Porto Alegre, 2350 Ramiro Barcelos Street, Porto Alegre, 90035-903, Brazil

    Lucas Miyake Okumura

Authors
  1. Lucas Miyake Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucas Miyake Okumura.

Ethics declarations

Conflict of interest

The author declares that there are no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okumura, L.M. How to report adherence to treatment as clinically relevant data—making a case of CML and TKI. Support Care Cancer 26, 323–324 (2018). https://doi.org/10.1007/s00520-017-3809-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-017-3809-2

Search

Navigation